Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lung Non-Squamous Non-Small Cell Carcinoma 1 Lung Diseases 1 Carcinoma 1

Interventions

Cisplatin 24 Carboplatin 19 Paclitaxel 18 pembrolizumab 12 Gemcitabine 12 Radiotherapy 9 Fluorouracil 9 Specimen Handling 8 Magnetic Resonance Spectroscopy 7 cemiplimab 6 Platinum 6 Nivolumab 6 Docetaxel 6 Cetuximab 6 1,2-diaminocyclohexaneplatinum II citrate 6 epothilone B 5 anlotinib 5 Sunitinib 5 Pemetrexed 5 Oxaliplatin 5 Everolimus 5 Drug Therapy 5 Cyclophosphamide 5 Capecitabine 5 Bevacizumab 5 durvalumab 4 Radiotherapy, Intensity-Modulated 4 Radiation 4 Erlotinib Hydrochloride 4 Celecoxib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma × zipalertinib × Clear all

NCT05967689 2026-05-28

REZILIENT2

Taiho Oncology, Inc.

Phase 2 Recruiting

Carcinoma, Lung Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡